AbbVie Advances Multi-Target IBD Strategy with Combination Therapies and Subcutaneous SKYRIZI Data Expected
核心洞察
AbbVie (搜索) expects double-blind week-16 data for lutikizumab and RINVOQ in hidradenitis suppurativa (搜索) by year-end, building on strong phase 2 results for lutikizumab in TNF-experienced patients.
The company is pursuing combination strategies in IBD using alpha-4 beta-7 (搜索), TL1A (搜索), lutikizumab, and TREM1 (搜索) to improve efficacy, durability and remission rates.
Subcutaneous formulation data for SKYRIZI are anticipated this year, while SKYRIZI/TL1A (搜索) combination studies are expected to begin later in 2024.
AbbVie (搜索) outlined an ambitious multi-target approach for inflammatory bowel disease (搜索) (IBD) treatment during a recent conference, highlighting expected data readouts and combination therapy strategies designed to enhance treatment outcomes across multiple inflammatory conditions.
Hidradenitis Suppurativa Data Expected by Year-End
The company anticipates double-blind week-16 data for both lutikizumab, an IL-1α/β (搜索) bispecific antibody, and RINVOQ in hidradenitis suppurativa (搜索) (HS) patients before the end of 2024. AbbVie (搜索) cited strong phase 2 results for lutikizumab, including efficacy in TNF-experienced patients, supporting the rationale for dual IL-1 blockade to target neutrophil-driven disease mechanisms.
IBD Combination Strategy Takes Shape
AbbVie (搜索) is pursuing an aggressive combination approach in IBD, targeting multiple pathways simultaneously to improve efficacy, durability, and remission rates. The strategy encompasses four key targets: alpha-4 beta-7 (搜索), TL1A (搜索), lutikizumab, and TREM1 (搜索).
The company's alpha-4 beta-7 (搜索) inhibitor is described as a more potent version compared with vedolizumab, with readout data expected this year. For TL1A (搜索) targeting, AbbVie (搜索) reported convincing phase 2 efficacy across the therapeutic class, with particularly stronger results in ulcerative colitis (搜索) compared to Crohn's disease (搜索). SKYRIZI/TL1A combination studies are planned to commence later this year.
Lutikizumab showed numerical superiority over HUMIRA in ulcerative colitis (搜索), though AbbVie (搜索) noted the results were not as high as desired. The company plans to test lutikizumab in Crohn's disease (搜索), including in combination with alpha-4 beta-7 (搜索). TREM1 (搜索) is positioned as targeting a unique, upstream inflammation-amplification mechanism, with proof-of-concept data expected later this year or early next year.
SKYRIZI Subcutaneous Formulation Advances
Subcutaneous formulation data for SKYRIZI are expected this year, potentially expanding administration options for the IL-23 (搜索) inhibitor currently approved for multiple inflammatory conditions.
Next-Generation Platform Development
Beyond current combination strategies, AbbVie (搜索) is advancing next-generation therapeutic platforms. The company is developing an oral IL-23 (搜索) program through its Nimble (搜索) partnership and B-cell-focused assets including a CD19 (搜索) antibody-drug conjugate (ADC 319) and ABBV-519. Additionally, AbbVie has partnered on an in-situ lipid nanoparticle (LNP) CAR-T approach, reflecting strategic investments in enhanced potency, durability, and anti-fibrotic therapeutic opportunities.